Attorneys for Plaintiffs UNITED STATES	DISTRICT COURT						
UNITED STATES	DISTRICT COURT						
	DISTRICT COURT						
	ριςτρίατ αρμρτ						
SOUTHERN DISTRI	UNITED STATES DISTRICT COURT						
SOUTHERI'DISTRI	CT OF CALIFORNIA						
C.B. and R.V.H., individually and on behalf of all others similarly situated,	Case No. '23CV0669 L BGS						
Plaintiffs,	CLASS ACTION COMPLAINT						
V.							
ASHLYNN MARKETING GROUP, NC.,	JURY TRIAL DEMANDED						
Defendant.							
	ASHLYNN MARKETING GROUP, NC.,						

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Plaintiffs C.B. and R.V.H. ("Plaintiffs") bring this action on behalf of themselves and all others similarly situated against Defendant Ashlynn Marketing Group, Inc., d/b/a Krave Botanicals ("Defendant" or "Krave").

NATURE OF THE ACTION

This is a civil class action lawsuit against Defendant Ashlynn Marketing 1. Group, Inc. for false, misleading, deceptive, and negligent sales practices regarding its kratom powder, capsule, and liquid extract products (the "Products"). Kratom is a dried leaf that is sold as a loose powder, packaged into gel caps, or made into an extract. However, what reasonable consumers do not know, and what Defendant fails to disclose, is that the "active ingredients" in kratom are similar to opioids. That is, kratom works on the exact same opioid receptors in the human brain as morphine and its analogs, has similar effects as such, and critically, has similar risks of physical addiction and dependency, with similar withdrawal symptoms. When reasonable consumers think of opiates and opioids, they think of heroin, fentanyl, hydrocodone, oxycodone, and morphine; they do not expect that the "all natural" product bought at their local corner store operates like an opioid, with similar addiction and dependency risks. Kratom is perniciously addictive – on a whole different level than caffeine or nicotine – and it has sunk its hooks into tens of thousands of unsuspecting consumers and caused them serious physical, psychological, and financial harm. Here, Defendant intentionally and negligently failed to disclose these material facts anywhere on its labeling, packaging, or marketing materials, and it has violated warranty law and state consumer protection laws in the process.

2. Defendant relies on its Products' innocuous packaging and the public's limited knowledge about kratom and its pharmacology to get users addicted, while reaping profits along the way. Reasonable consumers do not expect the bottles and pouches of kratom powder, which they can purchase at gas stations and corner stores, to be like an opioid with the same addictive potential of morphine and its analogs. Defendant relies on this ignorance and does nothing to correct it. Such activity is outrageous and is in contravention of California law and public policy.

3 4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

3.

1

2

Plaintiffs seek relief in this action individually and as a class action on behalf of similarly situated purchasers of Defendant's Products, for: (i) violation of California's Unfair Competition Law ("UCL"), Cal. Bus. & Prof. Code §§ 17200, et seq.; (ii) violation of California's Consumers Legal Remedies Act ("CLRA"), Cal. Civil Code §§ 1750, et seq.; (iii) violation of California's False Advertising Law ("FAL"), Cal. Bus. & Prof. Code §§ 17500, et seq.; (iv) breach of implied warranty; (v) unjust enrichment; (vi) fraud by omission; and (vii) negligent misrepresentation.

Because this action concerns issues of addiction and medical status, 4. Plaintiffs are filing under their initials for the sake of their personal privacy. Plaintiffs are reasonable consumers who fell victim to Defendant's omissions and misrepresentations about the addictive nature of kratom, which operates like an opioid, and became addicted as a result. Since addiction issues still wrongly carry somewhat of a stigma, Plaintiffs are filing this matter anonymously but will reveal their names as necessary to the Court under seal.

PARTIES

5. Plaintiff R.V.H. is a citizen of Arizona who resides in Yuma, Arizona.

Plaintiff C.B. is a citizen of California who resides in Encinitas, 6. California.

Defendant Ashlynn Marketing Group, Inc., is a California corporation 7. with its principal place of business in Santee, California.

8. Plaintiffs reserve the right to amend this Complaint to add different or additional defendants, including without limitation any officer, director, employee, supplier, or distributor of Defendant who has knowingly and willfully aided, abetted, and/or conspired in the false and deceptive conduct alleged herein.

JURISDICTION AND VENUE

9. This Court has subject matter jurisdiction pursuant to 28 U.S.C. § 1332(d)(2)(A) because this case is a class action where the aggregate claims of all members of the proposed class are in excess of \$5,000,000.00, exclusive of interest and costs, and at least one member of the proposed class is citizen of state different from Defendant.

10. This Court has general jurisdiction over Defendant because Defendant is a California corporation and maintains its principal place of business within this District.

11. Pursuant to 28 U.S.C. § 1391, this Court is the proper venue for this action because Defendant resides in this District.

FACTUAL ALLEGATIONS

Background and Pharmacology of Kratom

12. Kratom is a drug¹ which is derived from the kratom plant, *mitragyna speciosa*, indigenous to Southeast Asia, where it has been used in herbal medicine since at least the early 19th Century. Use of the plant has been particularly well-documented in Thailand, Indonesia, and Malaysia, and it remains popular in each of those countries to this day. Kratom is the most widely used drug in Thailand, for example.

13. The first reported use of Kratom in the scientific literature dates back to 1836 when it was noted that the leaves of the tree were used by Malays as a substitute for opium.

14. The plant's leaves are harvested, dried, and crushed into a fine powder which is then packaged, either straight into a pouch or in capsules, and sold by manufacturers like Krave. The drug can also be extracted into a liquid formulation, colloquially called a kratom "shot."

¹ Kratom is unregulated by the FDA, so the usage of the word "drug" here is meant in the colloquial sense, rather than as a defined term under the Food, Drug, and Cosmetic Act.

15. In the West, Kratom is sold through the Internet and at herbal stores, gas stations, corner stores, smoke shops, and "head" shops where it is primarily marketed as an herbal medicine or supplement to treat a variety of ailments (*e.g.*, pain, mental health, opioid withdrawal symptoms), as well as a "legal" or "natural" high by some manufacturers.

16. The chemicals in the plant which produce psychoactive effects when ingested are called "alkaloids."

17. The primary alkaloids in kratom plant leaves responsible for the kratom "high" are <u>Mitragynine</u>² ("MG") and <u>7-hydroxymitragynine</u> ("7-MG").

18. MG and 7-MG exhibit a wide variety of pharmacological effects, resulting in a highly dose-dependent response. For example, a low dose (0.5 grams to 3 grams) of kratom is typically described as stimulating or energizing, whereas a high dose (3+ grams) is described as euphoric, sedating, and analgesic. On the whole, however, kratom's high is not overwhelming like it would be for a "hard" drug like cocaine or heroin – it is somewhat more subtle, but its effects are nonetheless substantially similar to opiate-based painkillers such as hydrocodone and oxycodone in sufficient dosages.

19. Kratom's variable but not debilitating effects have always been part of its appeal. For instance, the use of kratom in Southeast Asia has been documented back for at least 150 years, and the earliest accounts described both a stimulant effect for use in hard day-labor when fresh leaves are chewed, and an analgesic and relaxing effect if brewed into a tea at the end of the day.

20. MG and 7-MG produce such a wide spectrum of effects because they interact with many different receptors in the brain. Studies have shown that MG and 7-MG interact with alpha-2 adrenergic receptors (adrenaline), D2 dopamine

² Pronounced "Mitra-Guy-Neen."

receptors, and the serotonin receptors 5-HT2A and 5-HT2C, all of which contribute to the drug's mood-lifting and stimulant-like effects.

21. Most crucially, MG and 7-MG also interact with the mu-opioid receptor.

22. The mu-opioid receptor is known as "the gateway to addiction" because it is the receptor which all opiates/opioids interact with to produce the classic opiate high: euphoric, sedating, and analgesic. This means that MG and 7-MG interact with the primary receptor that heroin and oxycodone interact with.

23. There are other opioid receptors, but the mu-opioid receptor produces the most "hedonic" or habit-forming effects such as euphoria and analgesia.

24. Mitragynine and 7-hydroxymitragynine were found to be more potent to the mu-opioid receptor than morphine via oral administration, according to one 2004 study, though the actual effect of kratom is dose-dependent, as discussed above.

25. Kratom is therefore considered by health professionals to be similar to an "opioid" and a "quasi-opiate."

26. The notion that kratom is substantially similar to an opioid, and a quasiopiate, is reaffirmed by a few facts. First, kratom's effects are very similar to those of other opioids. Second, when administered, kratom alleviates opioid withdrawal symptoms. Third, repeated use of kratom in itself results in opioid withdrawal symptoms.

27. All substances which act on the opioid receptors carry a very high risk of addiction, and kratom is no exception.

28. Addiction occurs when an opioid is ingested on a regular basis. Over time, the user develops a tolerance to the drug, requiring increased dosages to get the same effects as a lower dose used to have. As the dosages go up, the body becomes dependent on some amount of the drug to feel normal. When the drug is suddenly taken away, the user feels much worse than before they started taking the drug: this is what is known as withdrawal.

29. Opioids are addictive not just because of the pleasurable effects that they produce, but because sudden cessation of opioid use causes severe withdrawal symptoms which users feel compelled to avoid by taking more of the drug. The tragedy of addiction is that users want to stop, but they cannot.

30. The symptoms of kratom withdrawal are very similar to those of traditional opiate withdrawal. Such symptoms include: irritability, anxiety, difficulty concentrating, depression, sleep disturbance including restless legs, tearing up, runny nose, muscle and bone pain, muscle spasms, diarrhea, decreased appetite, chills, inability to control temperature, and extreme dysphoria and malaise.

31. Users typically start substances like kratom because of how good it makes them feel, but, once addicted, they use them to avoid the pain of withdrawal. It no longer is about getting high, but about not feeling "sick."

32. With kratom in particular, users note that the addiction sneaks up on them, and that it feels as though, over time, the color has been sapped from their lives. Long term users of kratom have reported experiencing depression, anxiety, anhedonia, and reduced sex drive.

Kratom Use and Addiction in the United States

33. Kratom use in the United States has exploded in popularity over the past decade. As of 2021, the American Kratom Association estimates that kratom is a \$1.3 billion a year industry, with 11 million to 15 million annual users in the United States.

Other studies have found that about 1 million people use kratom in the 34. United States every month. Two-thirds of those users use kratom daily.

Kratom's popularity can be attributed to a number of factors: first, it is 35. often marketed as a safe substitute for painkillers and appeals to those who falsely equate "natural" with "safe;" second, it has received attention from the media as a "nootropic" or "smart" drug because it is stimulating at low doses; third, its popularity has grown simply because it is so widely available, it produces a

pleasurable high, and it is unregulated; and finally, users are unaware that it is similar to an opioid with opioid addiction potential.

36. On the whole, however, kratom is a relatively unknown drug to the average consumer. Most people in the United States have never heard of it.

37. The advertisements and commentary about kratom say that it is like a substitute for coffee, a pain reliever, a treatment for opioid withdrawal, an antidepressant, an anti-anxiety supplement, and that it improves focus and gives users a boost of energy to get through the day. These advertisements universally espouse the purported benefits that kratom use can provide, without disclosing that the drug is similar to an opioid with the addictive potential of one.

38. What's more, because kratom does not produce a debilitating "high" like cocaine or heroin, it is very easy for users to take the drug every day without feeling as though they are developing a drug addiction or harming themselves. This makes kratom a particularly insidious drug because addiction can sneak up on unsuspecting users and can hold them in its grip despite their best efforts to stop using. The advertisements and word-of-mouth disclosures do not make this clear to consumers.

39. Because the manufacturers and advertisers do not disclose the addictive potential of this drug, many users have found themselves blindsided when they wake up one morning in the throes of withdrawal after having stopped using what they thought was an innocuous supplement. They then discover just how painfully dependent they have become on kratom. Because kratom is relatively unknown in the United States, many did not know where to turn for resources and aid. Some users come together on the Internet to share their experiences and support each other as they attempt to get off the drug. There are even well-populated and very active Internet forums serving as support groups for those struggling with and recovering from kratom addiction.

28

27

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

40. The reports from users who have fallen into addiction, or succeeded in escaping the drug's grasp, are heart-wrenching. Consistent amongst these reports is the initial shock that users felt when they realized they had become unwittingly addicted, and just how difficult it was for them to stop. Below are just a few accounts from the "Quitting Kratom" forum on www.reddit.com, which has 33,700 members as of January 2023:

About 8 months ago, one user wrote: "I've been on a 50gpd [grams per day] habit for about 4 years. Like most people here, <u>I was in denial that the Kratom was causing my multitude of issues. How could it be the Kratom when everyone keeps telling me how great it is? I made myself believe that I had underlying issues that the Kratom was helping. Spoiler: It wasn't. <u>I slowly became a shell of the person I used to be. TRUE clinical depression symptoms with zero joy in my life.</u> I started browsing this subreddit and reading everyone's stories and I related to every single one. Everyone had the same exact experience I had and at that moment I knew it was the Kratom causing my depression." (emphasis added).
</u>

About 2 years ago, another user wrote: "I saw 'A Leaf of Faith' and got the impression that kratom was a generally friendly substance to use freely, never knowing how addictive it was, how much it was further numbing me beyond how alcohol already was, how it was slowly wiping out my sex drive, and likely contributing to my perpetual brain fog. ... My second attempt [at quitting] was maybe another 7 or 8 months later. Kratom was making me pretty miserable. I was reading posts in this subreddit and I was finally aware of how addicted I was; feeling crappy, sluggish, and sorta spacey pretty much all the time."

About 2 years ago, another user wrote: "What a difficult journey it has been. I was a ~75 GPD [grams per day] user. <u>Quitting kratom was one of the hardest</u> <u>things I've had to do in my life.</u> I learned the hard way that kratom causes withdrawals on a work trip 3 years ago. I should have stopped then and there but I gave in because the RLS was so bad. ... Kratom withdrawal is seriously no joke so don't think you're the only one struggling so much. I'm only a week free but after this experience I know for sure that I will never go back. Good luck everyone!" (emphasis added).

About 2 years ago, another user wrote a post titled *Kratom Is An Addictive Drug.* It said, in part: "It's been 23 hours since my last dose. I just wanted to give my story hoping that it would help others see that they've been lied to, deceived and manipulated into thinking this plant is 'harmless and safe'. As a matter of fact, reading the horror stories on this subreddit was the first step in my recovery... I started taking it almost 3 years ago after hearing about it on...

1	well, Reddit. They touted it is a miracle plant that had all the benefits of an opioid with none of the side effects." (emphasis added).
2	About 10 months and another user wheter "I think the mentant would to describe
3	About 10 months ago, another user wrote: "I think the perfect word to describe Kratom addiction is 'insidious'. Here is the definition – ' <i>proceeding in a</i>
4 5	<i>gradual, subtle way, but with harmful effects.</i> 'I think this is why it takes so long to realize what is going on. There was never a rock bottom moment for me like there would be for other more conventional abused drugs. No
6	overdose, no bad behavior, no abusiveness to my family, no DWI, etc It
7	was just a lazy, slow descent into nothingness. I was living in a groundhogs day type of existence. Wake up, go to work, leave work, buy an extract shot or
8	2, have dinner, drink my shot, mindlessly look at my phone and/or watch TV. Wake up and do it all over again." (emphasis in original).
9	About 3 months ago, another user wrote: "I started using k[ratom] when I had
10	knee surgery Dec 2019 so 3 years. <u>I didn't want to use pain killers because I</u> got sober from alcohol 3/6/2018 and i felt the pain killers were going to make
11	me relapse. I didn't know I would end up in a worst place as I am now." (emphasis added).
12	
13	About 2 years ago, another user wrote: "Was in bed all day yesterday fighting withdrawals. I used to even be an athlete - strong lean and fit, until I got on
14	[kratom] shots and extracts. Didn't even get high any more - just wanted to not feel bad."
15	About A years ago, another user wroter "I researched brotom before using it
16	About 4 years ago, another user wrote: "I researched kratom before using it and almost every site promoted that its harmless with healthy benefits, and
17	that its withdrawals are like coffee for 3 days max. Information wasn't clear that kratom could become a negative addiction that takes months to recover"
18	"I took something I thought was helping me for 1.5-2 years, not even knowing the downsides be that information was so misleading. It fucked up
19	my digestion, energy, mood, brain fog, anxiety, etc. Fuck kratom, and fuck those who peddle it as a harmless cure-all."
20	
21	About 1 month ago, another user wrote: "For any newcomers: this stuff is absolutely no joke. It's not harmless and the wd [withdrawal]
22	is <i>definitely</i> not like caffeine. I've cold turkey'd caffeine before and I had a slight headache for a couple hours. I definitely have never woken up in a pool
23	of my own sweat from not having my caffeine This stuff is a drug. A
24	serious drug. And it's super freakin addictive. Extracts, powder, or in my case, capsulesit doesn't matter. Yes some forms are more addictive than others
25	but the WD is hellacious no matter how you're taking it." (emphasis original).
26	About 1 month ago, another user wrote: "This stuff is a drug, and dangerous! <u>I</u> started taking it because of all the good things I heard and read about it. I've
27	never been addicted to or dependent on anything before, but this stuff has
28	totally taken control of my life." (emphasis added).
	9 CLASS ACTION COMPLAINT – JURY TRIAL DEMANDED

Less than a month ago, another user wrote: "I finally realized a few weeks ago how much of a negative impact kratom was having on my life. I noticed myself planning my whole day around my doses and making sure when I left the house I'd bring an extra dose with me in a shaker bottle. It was heavily affecting my mood overall, but especially in public settings. I did not want to leave my house most days even if I did dose."

41. This Internet forum is filled with accounts just like these. The stories are consistent – well-meaning people who were looking to feel better, in mind body and spirit, by taking an "herbal supplement," only to end up with an opioid-like addiction.

42. What is particularly insidious about kratom is that, at the early stages, many users are unaware of its negative side effects and its addictive potential, so when they begin to experience the malaise of addiction they do not attribute it to the kratom. Rather, they take more of the substance thinking that it is helping them with their malaise.

43. As these accounts make clear, the addictive potential of kratom is a material fact to reasonable consumers which would help inform their purchase and consumption decisions. Defendant's products have no information, whatsoever, that kratom is similar to an opioid, is habit-forming, and that regular use will result in opioid-like dependency, with withdrawal symptoms similar to those of traditional opioids.

44. Consumers who knew the truth about kratom may not have purchased Defendant's Products or would have paid less than they did for them.

Defendant Knew or Should Have Known it was Selling a Highly Addictive Drug to Unsuspecting Consumers

45. Despite its traditional medical uses, kratom dependence has been known and observed for a long time and is well-documented in Southeast Asia, where the plaint originates and has a longer period of historic use.

10

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

46. Addiction to kratom among users in Thailand and Malaysia has been documented by scientists and researchers in the United States since at least 1988.

47. Upon information and belief, Defendant has interacted with growers and distributors in Southeast Asia who have disclosed the addictive nature of kratom to it.

48. Even without such interactions, Defendant has received numerous user reports about the addictive potential of kratom in the United States.

49. Defendant therefore knew or should have known that the Products it was selling were highly addictive.

50. Despite this knowledge, Defendant has failed to disclose the addictive potential of kratom on its website or on its Products' packaging.

51. The furthest that Defendant goes in "disclosing" the addictive nature of kratom is a single sentence buried in the "Learn More" page for its kratom powder product on its website. It states that "scientists are still conducting comprehensive studies to determine whether abusing Kratom causes addiction, death, and withdrawal symptoms." This is deliberately false and misleading. The addictiveness of kratom has been well-documented for decades and is an established fact in medical literature. The pharmacological effects of MG and 7-MG have been thoroughly studied, and it is well-established that MG and 7-MG act on the same mu-opioid receptors in the brain as traditional opioids. Further, there are widespread user reports and case studies of addiction and dependency issues.

52. To reiterate, this is not an instance where the science is still up for debate. It has been known for decades in the English-speaking world that kratom is highly addictive and has the potential to cause physical and psychological dependence in regular users. It has been known for over a century in Southeast Asia that kratom is addictive.

53. For example, kratom is the most commonly used drug in Thailand. A 2007 study found that 2.3% of people in Thailand have used kratom. Many of those users have developed a dependence on kratom to avoid withdrawal.

54. On information and belief, Defendant imports some of its kratom Products from Thailand.

55. Defendant therefore knows or should have known that kratom users can develop an addiction. Yet, Defendant fails to disclose this material fact on its website or its Products' packaging.

56. Defendant's Products' packaging, in particular, is woefully sparse. A representative image of Defendant's Products is depicted below:



57. On the back of each Product's packaging is a bog-standard disclaimer stating that the Products are not regulated or evaluated by the FDA.

58. There is no warning to consumers that the product interacts with opioid receptors, nor is there any warning that the product is highly addictive and that it should not be taken on a daily basis. To the contrary, the packaging proudly states "All Natural." Further, the company logo includes a pleasant-looking green leaf, and on the back of the packaging there is a banner of a leaf pattern colored with a rainbow. Nothing about this packaging would lead reasonable consumers to believe they were purchasing compounds similar to opioids, that function on the same muopioid receptors in the brain. It looks as innocuous as a vitamin supplement.

59. Reasonable consumers looking at the Products' packaging would not presume that kratom is highly addictive.

60. Defendant's website is rife with praise for kratom, with no warning that its Products are addictive. For example, upon inspecting the "kratom powder" section of the website, the first sentence they encounter is: "Kratom is not a recent discovery. The truth is it has been around for hundreds of years. This plant-based powder has been growing in popularity recently due to its many benefits and effects."

61. A bit further down, Defendant states: "For instance, some loyal Kratom users say they use Kratom to manage and reduce pain. Others say Kratom helps them relax in difficult situations."

62. The only warning Defendant gives is its misleading statement that kratom's addictive potential is still being researched.

63. The "Kratom Capsules" section of Defendant's website is even more egregious. The first statement Defendant makes is: "Warm greetings to all the Kratom lovers! As we all know, Kratom is a phenomenal herb with some extraordinary benefits to make your daily life more comfortable."

64. Further down the page, Defendant states: "When taken in high doses, most Kratom capsules produce effects similar to sedatives or opioids. As a result, some people now use Kratom capsules as an alternative to opioids. Some are even using Kratom capsules to overcome withdrawal symptoms associated with opioid drugs."

65. Nowhere does Defendant mention that kratom presents the same addiction problems that former opioid users and other consumers would want to avoid. Those seeking help as they come off opioids may be drawn in by Defendant's statements about kratom without knowing that they risk trading one addiction for another.

66. Defendant tries to bolster its credibility by making the half-true claim that "[a] 2021 review by the World Health Organization's expert committee on drug dependence found insufficient evidence of severe effects that can make them add Kratom to the list of internationally controlled substances." However, what Defendant fails to mention is that the same report also states: "in humans, opioid-like withdrawal symptoms have been reported following cessation of kratom use," though "the withdrawal syndrome appears to be less severe than withdrawal from morphine."

67. While kratom withdrawal may be "less severe" than morphine withdrawal, that is hardly a seal of approval – morphine withdrawal is one of the most unpleasant experiences that one can endure in modern life. And kratom withdrawal, while perhaps "less severe" than morphine withdrawal, is still an "opioid-like withdrawal" (according to the World Health Organization), with the same physical and mental symptoms. And kratom is unquestionably addictive and habit-forming.

68. The risk of "opioid-like withdrawal symptoms" is a material fact to reasonable consumers.

28

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

69. As a kratom product manufacturer and distributor, Defendant occupieda position of superior knowledge to the average reasonable consumer, who likelyknows next to nothing about kratom.

70. Defendant, through its misleading advertising and its failure to disclose kratom's addictive properties on its Products' labels, relied upon the average consumer's incomplete knowledge of kratom to sell its Products and get users addicted to kratom.

71. Defendant fails to disclose kratom's addictive potential because Defendant knows that it is a material fact to reasonable consumers which would influence their purchasing and consumption decisions, likely to Defendant's detriment.

72. By any metric, Defendant's conduct is immoral, unethical, and contrary to California public policy.

73. The United States is going through an opiate crisis that is shaking the foundations of our society. Amid this crisis, Defendant is creating more addicts for no reason other than to line its pockets, without adequate disclosures of its products' risks and through the use of false and misleading packaging. That cannot – and should not – be allowed, at least when their conduct entails breaches of warranty and violation of state consumer protection statutes (as it does here).

Plaintiffs' Experiences

74. Plaintiff C.B. first heard about kratom through a friend who did not mention the risks of dependency or addiction. As such, C.B. did not know that kratom was addictive and had no reason to know. He began purchasing Krave branded kratom capsules in 2018. When C.B. made his first purchase, he reviewed the Krave packaging and labels, but there were no disclosures on the bottle that would have corrected his misimpression. Because there were no disclosures, C.B. thought that Krave kratom could be consumed every day without the risk of physical dependence. C.B. soon discovered that Krave kratom was, in fact, addictive, and

CLASS ACTION COMPLAINT – JURY TRIAL DEMANDED

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

found himself requiring larger and larger doses to stave off withdrawal. For four years, C.B. took 20-25 grams of Krave Botanicals kratom capsules every day. When C.B. attempted to cease using kratom he was wracked by intense physical and psychological withdrawal symptoms that were substantially similar to traditional opiates. C.B. realized he was addicted to kratom in late 2020 and felt that he was being held captive by the specter of withdrawal. Though C.B. wanted to stop, he could not. At its worst, C.B.'s addiction to Krave kratom was costing him thousands of dollars a month. C.B. was eventually able to kick his addiction to Krave kratom, but not without going through intense physical and psychological withdrawals. Had C.B. known that kratom was so addictive, and that cessation would be so difficult, he would never have purchased Defendant's Products. C.B. made his purchases in and around San Marcos, California.

75. Plaintiff R.V.H. first heard about kratom while listening to the Joe Rogan Experience podcast. The speakers on the show espoused the benefits of the drug without talking about its addictiveness or the terrible withdrawal symptoms. As such, R.V.H. did not know that kratom was addictive and had no reason to know. He began purchasing Krave branded kratom capsules in 2018. When R.V.H. made his first purchase, he reviewed the Krave packaging and labels, but there were no disclosures on the bottle that would have corrected his misimpression. Because there were no disclosures, R.V.H. thought that Krave kratom could be consumed every day without the risk of physical dependence. R.V.H.'s body eventually discovered that Krave kratom was, in fact, addictive, and he found himself requiring larger and larger doses to stave off withdrawal. For four years, R.V.H. took over 50 grams of Krave Botanicals kratom capsules every day. When R.V.H. attempted to cease using kratom he was wracked by intense physical and psychological withdrawal symptoms that were substantially similar to traditional opiates. At its worst, R.V.H.'s addiction to Krave kratom was costing him thousands of dollars a month. He would cash his check at the 8th Street Smoke Shop in Yuma, Arizona, and spend it immediately on

16

CLASS ACTION COMPLAINT – JURY TRIAL DEMANDED

more of the drug. R.V.H. realized he was addicted to kratom in June 2020 and felt 1 that he was being held captive by kratom. Though R.V.H. wanted to stop, he could 2 not. R.V.H. was eventually able to kick his addiction to Krave kratom, but not 3 without going through intense physical and psychological withdrawals and 4 undergoing treatment at a suboxone clinic. Had R.V.H. known that kratom was so 5 addictive, and that cessation would be so difficult, he would never have purchased 6 Defendant's Product. R.V.H. made his purchases in and around Yuma, Arizona. 7 **CLASS ALLEGATIONS** 8 76. 9 *Class Definitions*. Plaintiffs bring this action pursuant to Code of Civil Procedure § 382 and Civil Code § 1781 on behalf of classes of similarly situated 10 individuals, defined as follows: 11 All persons nationwide who, within the applicable statute of limitations period, up to and including the date of final judgement in this action, purchased Krave Botanicals kratom products (the "Class") 12 13 All Class members in California who, within the applicable statute of limitations period, up to and including the date of 14 final judgment in this action, purchased Krave Botanicals kratom products (the "California Class"). 15 16 All Class members in Arizona who, within the applicable statute of limitations period, up to and including the date of 17 final judgment in this action, purchased Krave Botanicals kratom products (the "Arizona Class"). 18 77. Specifically excluded from the Class are Defendant and any entities in 19 which Defendant have a controlling interest, Defendant's agents and employees, the 20 judge to whom this action is assigned, members of the judge's staff, and the judge's 21 immediate family. 22 Plaintiffs reserve the right to amend the definitions of the Classes if 78. 23 discovery or further investigation reveals that the Class should be expanded or 24 otherwise modified. 25 79. *Numerosity.* Members of the Class are so numerous that their 26 individual joinder herein is impracticable. On information and belief, the Class 27 comprises at least thousands of consumers throughout California and the United 28 17 CLASS ACTION COMPLAINT – JURY TRIAL DEMANDED

2

3

4

5

6

7

8

States. The precise number of Class members and their identities are unknown to
Plaintiffs at this time but may be determined through discovery. Class members may
be notified of the pendency of this action by mail and/or publication through the
distribution records of Defendant.

80. *Commonality and Predominance*. Common questions of law and fact exist as to all Class members and predominate over questions affecting only individual Class members. Common legal and factual questions include, but are not limited to:

9	a. whether the labels on Defendant's Products have the capacity to						
10	mislead reasonable consumers;						
11	b. whether Defendant knew that kratom is a highly addictive substance;						
12	c. whether Defendant's conduct alleged herein violated California's						
13	False Advertising Law ("FAL"), Cal. Bus. & Prof. Code §§ 17500,						
14	et seq., California's Consumers Legal Remedies Act ("CLRA"), Cal.						
15	Civ. Code §§ 1750, et seq., and/or California's Unfair Competition						
16	Law ("UCL"), Cal. Bus. & Prof. Code §§ 17200, et seq.;						
17	d. whether Defendant's conduct alleged herein constitutes unjust						
18	enrichment;						
19	e. whether Defendant's conduct constitutes negligent omission;						
20	f. whether Plaintiffs and the Class are entitled to damages and/or						
21	restitution;						
22	g. whether Plaintiffs and the Class are entitled to attorneys' fees and						
23	costs under California Code of Civil Procedure § 1021.5.						
24	81. <i>Typicality.</i> The claims of Plaintiffs are typical of the claims of the Class						
25	in that Plaintiffs and the Class sustained damages as a result of Defendant's uniform						
26	wrongful conduct, based upon Defendant's failure to inform Plaintiffs and all others						
27	similarly situated that its Products are highly addictive and akin to opioids.						
28							
	18 CLASS ACTION COMPLAINT HURY TRIAL DEMANDED						
	CLASS ACTION COMPLAINT – JURY TRIAL DEMANDED						

82. *Adequacy*. Plaintiffs will fairly and adequately protect Class members' interests. Plaintiffs have no interests antagonistic to Class members' interests, and Plaintiffs have retained counsel that have considerable experience and success in prosecuting complex class-actions and consumer-protection cases.

83. *Superiority*. A class action is superior to all other available methods for the fair and efficient adjudication of this controversy for, *inter alia*, the following reasons: prosecutions of individual actions are economically impractical for members of the Class; the Class is readily definable; prosecution as a class action avoids repetitious litigation and duplicative litigation costs, conserves judicial resources, and ensures uniformity of decisions; and prosecution as a class action permits claims to be handled in an orderly and expeditious manner.

84. Defendant has acted or failed to act on grounds generally applicable to the Class, thereby making appropriate final injunctive relief with respect to the Class as a whole.

85. Without a class action, Defendant will continue a course of action that will result in further damages to Plaintiffs and members of the Class and will likely retain the benefits of its wrongdoing.

86. Based on the foregoing allegations, Plaintiffs' claims for relief include those set forth below.

FIRST COUNT

Violations of California's Unfair Competition Law ("UCL"), Cal. Bus. & Prof. Code §§ 17200, et seq.

87. Plaintiff C.B. re-alleges and incorporates by reference every allegation set forth in the preceding paragraphs as though alleged in this Count.

88. Plaintiff C.B. brings this claim individually and on behalf of the members of the proposed California Class against Defendant.

89. The UCL prohibits unfair competition in the form of "any unlawful, unfair, or fraudulent business act or practice and unfair, deceptive, untrue or

1

misleading advertising and any act." Cal. Bus. & Prof. Code § 17200. A practice is unfair if it (1) offends public policy; (2) is immoral, unethical, oppressive, or unscrupulous; or (3) causes substantial injury to consumers. The UCL allows "a person who has suffered injury in fact and has lost money or property" to prosecute a civil action for violation of the UCL. Cal. Bus. & Prof. Code § 17204. Such a person may bring such an action on behalf of himself or herself and others similarly situated who are affected by the unlawful and/or unfair business practice or act.

90. As alleged below, Defendant has committed unlawful, fraudulent, and/or unfair business practices under the UCL by: (a) representing that Defendant's Products have certain characteristics that they do not, in violation of Cal. Civil Code \$ 1770(a)(5); (b) advertising goods and services with the intent not to sell them as advertised, in violation of Cal. Civil Code \$ 1770(a)(9); (c) selling addictive substances to unsuspecting consumers and profiting from their addiction; and (d) failing to disclose that its Products pose a serious risk of addiction;

91. Defendant's conduct has the capacity to mislead a significant portion of the general consuming public or of targeted consumers, acting reasonably in the circumstances.

92. Defendant's conduct has injured Plaintiff C.B. and the California Class he seeks to represent in that he paid money for a product that he would not have purchased or paid more than he would have but for Defendant's failure to disclose the addictive nature of its Products. Such injury is not outweighed by any countervailing benefits to consumers or competition. Indeed, no benefit to consumers or competition results from Defendant's conduct. Since consumers reasonably rely on Defendant's labels, and thus also its omissions, consumers could not have reasonably avoided such injury. *Davis v. Ford Motor Credit Co.*, 179 Cal. App. 4th 581, 597-98 (2009); *see also Drum v. San Fernando Valley Bar Ass 'n*, 182 Cal. App. 4th 247, 257 (2010) (outlining the third test based on the definition of "unfair" in Section 5 of the FTC Act).

1

2

20

CLASS ACTION COMPLAINT – JURY TRIAL DEMANDED

93. Pursuant to California Business and Professional Code § 17203,
Plaintiff C.B. and the California Class members seek an order of this Court that includes, but is not limited to, an order requiring Defendant to (a) provide restitution to Plaintiff C.B. and the other California Class members; (b) disgorge all revenues obtained as a result of violations of the UCL; and (c) pay Plaintiff C.B. and the California Class members' fees and costs.

94. Here, equitable relief is appropriate because Plaintiff C.B. may lack an adequate remedy at law if, for instance, damages resulting from their purchase of the Product is determined to be an amount less than the premium price of the Product. Without compensation for the full premium price of the Product, Plaintiff C.B. would be left without the parity in purchasing power to which they are entitled.

95. Injunctive relief is also appropriate, and indeed necessary, to require Defendant to provide full and accurate disclosures regarding the Product so that Plaintiff C.B. and the California Class members can reasonably rely on Defendant's packaging as well as those of Defendant's competitors who may then have an incentive to follow Defendant's deceptive practices, further misleading consumers.

96. Restitution and/or injunctive relief may also be more certain, prompt, and efficient than other legal remedies requested herein. The return of the full premium price, and an injunction requiring Defendant to disclose on its Products' packaging that kratom is addictive will ensure that Plaintiff C.B. is in the same place he would have been in had Defendant's wrongful conduct not occurred, *i.e.*, in the position to make an informed decision about the purchase of the Products absent omissions with the full purchase price at their disposal.

SECOND COUNT Violation of California's Consumers Legal Remedies Act, Cal. Civ. Code §§ 1750, *et seq*.

97. Plaintiff C.B. realleges and reincorporates by reference all paragraphs alleged above.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

98. Plaintiff C.B. brings this claim individually and on behalf of the California Class against Defendant.

99. Plaintiff C.B. and California Class Members are consumers within the meaning of Cal. Civ. Code § 1761(d).

100. Cal. Civ. Code § 1770(a)(5) prohibits "[r]epresenting that goods or services have sponsorship, approval, characteristics, ingredients, uses, benefits, or quantities which they do not have or that a person has a sponsorship, approval, status, affiliation, or connection which she or she does not have."

101. Cal. Civ. Code § 1770(a)(7) prohibits "[r]epresenting that goods or services are of a particular standard, quality, or grade, or that goods are of a particular style or model, if they are of another."

102. Cal. Civ. Code § 1770(a)(9) prohibits "advertising goods or services with intent not to sell them as advertised."

103. Defendant violated Cal. Civ. Code §§ 1770(a)(5), (a)(7), and (a)(9) by intentionally and misleadingly representing that its Products are "all natural" and by failing to disclose that its Products are addictive, a fact which is material to reasonable consumers.

104. Defendant's misrepresentations and omissions deceive and have a tendency and ability to deceive the general public.

105. Defendant has exclusive or superior knowledge of kratom's addictive nature, which was not known to Plaintiff C.B. or California Class Members.

106. Plaintiff C.B. and California Class Members have suffered harm as a result of these violations of the California Consumers Legal Remedies Act, Cal. Civ. Code §§ 1750, *et seq.* ("CLRA") because they have incurred charges and/or paid monies for the Products that they otherwise would not have incurred or paid had they known that kratom is addictive and causes withdrawals. As a result, Plaintiff C.B. and the California Class are entitled to actual damages in an amount to be proven at trial, reasonable attorneys' fees and costs, declaratory relief, and punitive damages.

107. On January 18, 2023, Plaintiff C.B.'s counsel sent Defendant a CLRA notice letter, which complies in all respects with Cal. Civ. Code § 1782(a). The letter was sent via certified mail, return receipt requested, advising Defendant that it was in violation of the CLRA and demanding that it cease and desist from such violations and make full restitution by refunding the monies received therefrom. The letter stated that it was sent on behalf of all other similarly situated purchasers.

<u>THIRD COUNT</u> Violation of California's False Advertising Law, Cal. Bus. & Prof. Code §§ 17500, *et seq*.

108. Plaintiff C.B. realleges and reincorporates by reference all paragraphs alleged above.

109. Plaintiff C.B. brings this claim individually and on behalf of the California Class against Defendant.

110. Defendant's acts and practices, as described herein, have deceived and/or are likely to continue to deceive California Class Members and the public. As described above, and throughout this Complaint, Defendant misrepresented that kratom is not addictive. Such representation is not true.

111. By its actions, Defendant disseminated uniform advertising regarding its kratom Products to and across California. The advertising was, by its very nature, unfair, deceptive, untrue, and misleading within the meaning of California's False Advertising Law, Cal. Bus. & Prof. Code §§ 17500, *et seq.* (the "FAL"). Such advertisements were intended to and likely did deceive the consuming public for the reasons detailed herein.

112. The above-described false, misleading, and deceptive advertising Defendant disseminated continues to have a likelihood to deceive in that Defendant continues to misrepresent, without qualification, that kratom is not addictive.

113. In making and disseminating these statements, Defendant knew, or should have known, its advertisements were untrue and misleading in violation of

California law. Defendant knows that kratom is addictive yet fails to disclose this fact to consumers.

114. Plaintiff C.B. and other California Class Members purchased KraveKratom based on Defendant's representations and omissions that kratom is not addictive.

115. The misrepresentations and non-disclosures by Defendant of the material facts described and detailed herein constitute false and misleading advertising and, therefore, constitutes a violation of the FAL.

116. As a result of Defendant's wrongful conduct, Plaintiff C.B. and California Class Members lost money in an amount to be proven at trial. Plaintiff C.B. and California Class Members are therefore entitled to restitution as appropriate for this cause of action.

117. Plaintiff C.B. and California Class Members seek all monetary and nonmonetary relief allowed by law, including restitution of all profits stemming from Defendant's unfair, unlawful, and fraudulent business practices; declaratory relief; reasonable attorneys' fees and costs under Cal. Code Civ. Proc. § 1021.5; and other appropriate equitable relief.

FOURTH COUNT Breach of Implied Warranty

118. Plaintiffs reallege and reincorporate by reference all paragraphs alleged above.

119. Plaintiffs bring this claim individually and on behalf of the nationwide Class, California Class, and Arizona Class against Defendant.

120. Defendant, as the designer, manufacturer, marketer, distributor, and/or seller of the Products, impliedly warranted that kratom is not addictive and does not cause opioid-like withdrawal symptoms because it did not provide a of disclosure on the Products' packaging stating otherwise.

121. Defendant breached its warranty implied in the contract for the sale of its kratom Products because the Products could not pass without objection in the trade under the contract description: the kratom Products were not adequately contained, packaged, and labeled as per Defendant's contract with Plaintiffs and members of the Class, and the Products do not conform to the implied affirmations of fact made on the marketing and packaging for the Products that the Products are not addictive and do not cause withdrawals. U.C.C. §§ 2-313(2)(a), (e), (f). As a result, Plaintiffs and members of the Classes did not receive the goods as impliedly warranted by Defendant to be merchantable.

122. Plaintiffs and members of the Class purchased the Products in reliance upon Defendant's skill and judgment and the implied warranties of fitness for the purpose.

123. The kratom Products were defective when they left the exclusive control of Defendant.

124. Plaintiffs and members of the Class did not receive the goods as warranted.

125. As a direct and proximate cause of Defendant's breach of the implied warranty, Plaintiffs and members of the Class have been injured and harmed because: (a) they would not have purchased Krave Kratom on the same terms if they knew that the Product was addictive and could cause opioid-like withdrawal symptoms; and (b) the Products do not have the characteristics, uses, or benefits as promised by Defendant.

126. On January 18, 2023, prior to filing this action, Defendant was served with a pre-suit notice letters on behalf of Plaintiffs that complied in all respects with U.C.C. §§ 2-314 and 2-607. Plaintiffs' counsel sent Defendant a letter advising Defendant that it breached an implied warranty and demanded that Defendant cease and desist from such breaches and make full restitution by refunding the monies received therefrom.

1

<u>FIFTH COUNT</u> Unjust Enrichment

127. Plaintiffs incorporate by reference the foregoing paragraphs of this Complaint as if fully stated herein.

128. Plaintiffs bring this claim individually and on behalf of the members of the nationwide Class, California Class, and Arizona Class against Defendant.

129. Plaintiffs and the Class members conferred a benefit on Defendant in the form of the gross revenues Defendant derived from the money they paid to Defendant.

130. Defendant had an appreciation or knowledge of the benefit conferred on it by Plaintiffs and the Class members.

131. Defendant has been unjustly enriched in retaining the revenues derived from Plaintiffs and the Class members' purchases of the Products, which retention of such revenues under these circumstances is unjust and inequitable because Defendant omitted that the Products were addictive and similar to opioids. This caused injuries to Plaintiffs and members of the Classes because they would not have purchased the Products or would have paid less for them if the true facts concerning the Products had been known.

132. Defendant accepted and retained the benefit in the amount of the gross revenues it derived from sales of the Products to Plaintiffs and the Class members.

133. Defendant has thereby profited by retaining the benefit under circumstances which would make it unjust for Defendant to retain the benefit.

134. Plaintiffs and the Class members are, therefore, entitled to restitution in the form of the revenues derived from Defendant's sale of the Products.

135. As a direct and proximate result of Defendant's actions, Plaintiffs and the members of the Class have suffered in an amount to be proven at trial.

136. Here, equitable relief is appropriate because Plaintiffs may lack an adequate remedy at law if, for instance, damages resulting from their purchase of the Product is determined to be an amount less than the premium price of the Product. Without compensation for the full premium price of the Product, Plaintiffs would be left without the parity in purchasing power to which they are entitled.

137. Injunctive relief is also appropriate, and indeed necessary, to require Defendant to provide full and accurate disclosures regarding the Product so that Plaintiffs and Class members can reasonably rely on Defendant's packaging as well as those of Defendant's competitors who may then have an incentive to follow Defendant's deceptive practices, further misleading consumers.

138. Restitution may also be more certain, prompt, and efficient than other legal remedies requested herein. The return of the full premium price will ensure that Plaintiffs are in the same place they would have been in had Defendant's wrongful conduct not occurred, i.e., in the position to make an informed decision about the purchase of the Products absent omissions with the full purchase price at their disposal.

<u>SIXTH COUNT</u> Fraud by Omission

139. Plaintiffs reallege and reincorporate by reference all paragraphs alleged above.

140. Plaintiffs bring this claim individually and on behalf of the nationwide Class, California Class, and Arizona Class against Defendant.

141. Defendant Ashlynn Marketing, Inc., is located in Santee, California.

142. Defendant distributed its Products throughout the State of California and the Nation.

143. Defendant misrepresented that its kratom Products have attributes or qualities that they do not have by failing to disclose that kratom is addictive and can cause opioid-like withdrawal.

28

1

2

3

144. Defendant knows that kratom is addictive because it interacts with kratom vendors and has been made aware of user reports.

145. Defendant knows that knowledge of kratom's addictive nature is a material fact that would influence the purchasing decision of reasonable consumers.

146. The average reasonable consumer in the kratom purchasing context does not know that kratom is addictive and cannot reasonably access that information.

147. Defendant therefore had a duty to Plaintiffs and the Class members to disclose that kratom is addictive and can cause withdrawals on the Products' packaging.

148. Consumers reasonably and justifiably relied on Defendant's omission because it is reasonable to assume that a product which is addictive like an opioid would bear a warning.

149. As a result of Defendant's omission, Plaintiffs and the Class memberspaid for kratom Products they may not have purchased, or paid more for thoseProducts than they would have had they known the truth about kratom.

SEVENTH COUNT Negligent Misrepresentation

150. Plaintiffs reallege and reincorporate by reference all paragraphs alleged above.

151. Plaintiffs bring this claim individually and on behalf of the nationwide Class, California Class, and Arizona Class against Defendant.

152. Defendant Ashlynn Marketing, Inc. is headquartered in Santee, California.

153. Defendant distributed its Products throughout the state of California.

154. Defendant misrepresented that its kratom Products have attributes or qualities that they do not have by failing to disclose that kratom is addictive and can cause opioid-like withdrawal. 155. Defendant knew or should have known that kratom is addictive because it interacts with kratom vendors and has been made aware of user reports and scientific studies.

156. Defendant knew or should have known that knowledge of kratom's addictive nature is a material fact that would influence the purchasing decision of reasonable consumers.

157. The average reasonable consumer in the kratom purchasing context does not know that kratom is addictive and cannot reasonably access that information.

158. Defendant therefore had a duty to Plaintiffs and the Class members to disclose that kratom is addictive and can cause withdrawals on the Products' packaging.

159. Consumers reasonably and justifiably relied on Defendant's omission because it is reasonable to assume that a product which is addictive like an opioid would bear some kind of a warning.

160. As a result of Defendant's omission, Plaintiffs and the Class members paid for kratom Products they may not have purchased or paid more for those Products than they would have had they known the truth about kratom.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs C.B. and R.V.H., individually and on behalf of all others similarly situated, seek judgment against Defendant, as follows:

a. For an order certifying the Class and naming Plaintiffs as the representatives of the Class, naming Plaintiff C.B. as representative of the California Class, Plaintiff R.V.H. as representative of the Arizona Class, and naming Plaintiffs' attorneys as Class Counsel to represent the Class, California Class, and Arizona Class;

b. For an order declaring Defendant's conduct violates the statutes referenced herein;

11 Plaintiffs demand a trial by jury on all claims so triable. 12 Dated: April 13, 2023 Respectfully submitted, 13 BURSOR & FISHER, P.A. 14 By: <u>/s/ Neal J. Deckant</u> Neal J. Deckant 16 Neal J. Deckant (State Bar No. 322946) 17 Neal J. Deckant (State Bar No. 322946) 18 Luke Sironski-White (State Bar No. 348441) 19 Walnut Creek, CA 94596 20 Telephone: (925) 300-4455 21 E-mail: ndeckant@bursor.com 22 Isironski@bursor.com 23 Attorneys for Plaintiffs 24 25 25 26	Ca	se 3:23-cv-0	0669-L-BGS	Document 1	Filed 04/13/23	PageID.31	Page 31 of 32			
3 d. For actual, compensatory, statutory, and/or punitive damages in amounts to be determined by the Court and/or jury; 4 e. For prejudgment interest on all amounts awarded; 5 f. For an order of restitution and all other forms of equitable monetary relief; 7 g. For injunctive relief as pleaded or as the Court may deem proper; and 8 attorneys' fees, expenses, and costs of suit. 9 IURY TRIAL DEMANDED 10 Plaintiffs demand a trial by jury on all claims so triable. 11 Dated: April 13, 2023 13 BuRSOR & FISHER, P.A. 14 Bursor & Fisher, P.A. 15 By:/s/ Neal J. Deckant										
 e. For prejudgment interest on all amounts awarded; f. For an order of restitution and all other forms of equitable monetary relief; g. For injunctive relief as pleaded or as the Court may deem proper; and h. For an order awarding Plaintiffs and the Class their reasonable attorneys' fees, expenses, and costs of suit. JURY TRIAL DEMANDED Plaintiffs demand a trial by jury on all claims so triable. Dated: April 13, 2023 Respectfully submitted, BURSOR & FISHER, P.A. By: <u>/s/Neal J. Deckant</u> Neal J. Deckant Neal J. Deckant (State Bar No. 322946) Luke Sironski-White (State Bar No. 348441) 1990 North California Blvd., Suite 940 Walnut Creek, CA 94596 Telephone: (925) 300-4455 Facsimile: (925) 300-4455 Facsimile: (925) 407-2700 E-mail: ndeckant@Dursor.com Jironski@bursor.com <i>Attorneys for Plaintiffs</i> 		d.	d. For actual, compensatory, statutory, and/or punitive damages in							
6 relief; 7 g. For injunctive relief as pleaded or as the Court may deem proper; and 8 h. For an order awarding Plaintiffs and the Class their reasonable attorneys' fees, expenses, and costs of suit. 9 JURY TRIAL DEMANDED 10 JURY TRIAL DEMANDED 11 Plaintiffs demand a trial by jury on all claims so triable. 12 Dated: April 13, 2023 13 BURSOR & FISHER, P.A. 14 BURSOR & FISHER, P.A. 15 By: <u>/s/ Neal J. Deckant</u> 16 Neal J. Deckant 17 Neal J. Deckant (State Bar No. 322946) 18 Luke Sironski-White (State Bar No. 342441) 190 Walnut Creek, CA 94596 20 Telephone: (925) 300-4455 21 E-mail: ndeckant@bursor.com 22 Isironski@bursor.com 23 Attorneys for Plaintiffs 24 25 25 26 27 30	4	e.								
7 g. For injunctive relief as pleaded or as the Court may deem proper; and 8 b. For an order awarding Plaintiffs and the Class their reasonable attorneys' fees, expenses, and costs of suit. 9 IURY TRIAL DEMANDED 10 IURY TRIAL DEMANDED 11 Plaintiffs demand a trial by jury on all claims so triable. 12 Dated: April 13, 2023 13 BURSOR & FISHER, P.A. 14 BURSOR & FISHER, P.A. 15 By: <u>/s/ Neal J. Deckant</u> Neal J. Deckant 16 Neal J. Deckant (State Bar No. 322946) Luke Sironski-White (State Bar No. 348441) 1990 North California Blvd., Suite 940 18 Luke Sironski-White (State Bar No. 348441) 1990 North California Blvd., Suite 940 19 Walnut Creek, CA 94596 20 Telephone: (925) 300-4455 21 E-mail: ndeckant@bursor.com 22 Isironski@bursor.com 23 Attorneys for Plaintiffs 24 25 25 30		f.	f. For an order of restitution and all other forms of equitable monetary							
8 h. For an order awarding Plaintiffs and the Class their reasonable attorneys' fees, expenses, and costs of suit. 9 JURY TRIAL DEMANDED 10 JURY TRIAL DEMANDED 11 Plaintiffs demand a trial by jury on all claims so triable. 12 Dated: April 13, 2023 13 Dated: April 13, 2023 14 BURSOR & FISHER, P.A. 15 By:/s/Neal J. DeckantNeal J. DeckantNeal J. Deckant 16 Neal J. Deckant (State Bar No. 322946) 18 Luke Sironski-White (State Bar No. 322946) 19 Walnut Creek, CA 94596 20 Telephone: (925) 300-4455 21 E-mail: ndeckant@bursor.com 22 Isironski@bursor.com 23 Attorneys for Plaintiffs 24 25 25 26 26 20		g.								
JURY TRIAL DEMANDED Plaintiffs demand a trial by jury on all claims so triable. Plaintiffs demand a trial by jury on all claims so triable. Dated: April 13, 2023 Respectfully submitted, BURSOR & FISHER, P.A. By: /s/ Neal J. Deckant Neal J. Deckant Neal J. Deckant Neal J. Deckant Neal J. Deckant (State Bar No. 322946) Luke Sironski-White (State Bar No. 348441) 199 Walnut Creek, CA 94596 Telephone: (925) 300-4455 Facsimile: (925) 407-2700 E-mail: ndeckant@bursor.com Isironski@bursor.com Attorneys for Plaintiffs 24 25 26 27 28 30	8	h.	8							
10 Plaintiffs demand a trial by jury on all claims so triable. 11 Plaintiffs demand a trial by jury on all claims so triable. 12 Dated: April 13, 2023 Respectfully submitted, 13 BURSOR & FISHER, P.A. 15 By: <u>/s/Neal J. Deckant</u> Neal J. Deckant 16 Neal J. Deckant (State Bar No. 322946) 17 Neal J. Deckant (State Bar No. 322946) 18 1990 North California Blvd., Suite 940 19 Walnut Creek, CA 94596 20 Telephone: (925) 300-4455 21 E-mail: ndeckant@bursor.com 22 Attorneys for Plaintiffs 23 Attorneys for Plaintiffs 24 25 25 26 27 28	9	JURY TRIAL DEMANDED								
11 Dated: April 13, 2023 Respectfully submitted, 13 BURSOR & FISHER, P.A. 14 Bursor & FISHER, P.A. 15 By: <u>/s/Neal J. Deckant</u> Neal J. Deckant 16 Neal J. Deckant (State Bar No. 322946) 17 Neal J. Deckant (State Bar No. 322946) 18 Luke Sironski-White (State Bar No. 348441) 19 Walnut Creek, CA 94596 20 Telephone: (925) 300-4455 21 Facsimile: (925) 407-2700 22 E-mail: ndeckant@bursor.com 23 Attorneys for Plaintiffs 24 25 25 30 26 30	10	Plain	ntiffs deman							
13 Dated: April 13, 2023 Respectfully submitted, 13 BURSOR & FISHER, P.A. 15 By: /s/ Neal J. Deckant 16 Neal J. Deckant 17 Neal J. Deckant (State Bar No. 322946) 18 Luke Sironski-White (State Bar No. 348441) 19 Value Sironski-White (State Bar No. 348441) 19 Walnut Creek, CA 94596 20 Telephone: (925) 300-4455 21 Facsimile: (925) 407-2700 22 E-mail: ndeckant@bursor.com 23 Attorneys for Plaintiffs 24 25 25 30 26 30	11									
14 BURSOR & FISHER, P.A. 15 By: /s/ Neal J. Deckant 16 Neal J. Deckant (State Bar No. 322946) 17 Neal J. Deckant (State Bar No. 322946) 18 Luke Sironski-White (State Bar No. 348441) 1900 North California Blvd., Suite 940 19 Walnut Creek, CA 94596 20 Telephone: (925) 300-4455 21 E-mail: ndeckant@bursor.com 22 Isironski@bursor.com 23 Attorneys for Plaintiffs 24 25 26 30		Dated: April 13, 2023 Respectfully submitted,								
15 By: /s/ Neal J. Deckant 16 Neal J. Deckant 17 Neal J. Deckant (State Bar No. 322946) 18 Luke Sironski-White (State Bar No. 348441) 19 Walnut Creek, CA 94596 20 Telephone: (925) 300-4455 21 E-mail: ndeckant@bursor.com 22 Isironski@bursor.com 23 Attorneys for Plaintiffs 24 25 26 30					BURSOR &	FISHER, I	P.A .			
16Neal J. Deckant17Neal J. Deckant (State Bar No. 322946) Luke Sironski-White (State Bar No. 348441) 1990 North California Blvd., Suite 940181990 North California Blvd., Suite 94019Walnut Creek, CA 94596 Telephone: (925) 300-4455 Facsimile: (925) 407-270020E-mail: ndeckant@bursor.com22Isironski@bursor.com23Attorneys for Plaintiffs24252630					$\mathbf{D}_{\mathbf{M}} = \frac{1}{2} \sqrt{N}$					
17 Neal J. Deckant (State Bar No. 322946) 18 Luke Sironski-White (State Bar No. 348441) 19 Walnut Creek, CA 94596 20 Telephone: (925) 300-4455 21 E-mail: ndeckant@bursor.com 22 Isironski@bursor.com 23 Attorneys for Plaintiffs 24 30	-				-					
18 Luke Sironski-White (State Bar No. 348441) 19 1900 North California Blvd., Suite 940 19 Walnut Creek, CA 94596 20 Telephone: (925) 300-4455 21 E-mail: ndeckant@bursor.com 22 Isironski@bursor.com 23 Attorneys for Plaintiffs 24 25 26 30					Neal J. Decka	nt (State Ba	ar No. 322946)			
191990 North California Blvd., Suite 94019Walnut Creek, CA 9459620Telephone: (925) 300-445521E-mail: ndeckant@bursor.com22lsironski@bursor.com23Attorneys for Plaintiffs24252630		Luke Sironski-White (State Bar No. 348441)								
20 Telephone: (925) 300-4455 21 Facsimile: (925) 407-2700 21 E-mail: ndeckant@bursor.com 22 lsironski@bursor.com 23 Attorneys for Plaintiffs 24 25 26 27 28 30										
Pacsimile: (925) 407-2700 21 E-mail: ndeckant@bursor.com 22 lsironski@bursor.com 23 Attorneys for Plaintiffs 24 25 26 27 28 30					Telephone: (9	25) 300-44	55			
 22 lsironski@bursor.com 23 Attorneys for Plaintiffs 24 25 26 27 28 30 										
23 Attorneys for Plaintiffs 24						-				
24 25 26 27 28 30					Attorneys for	Plaintiffs				
25 26 27 28 30										
26 27 28 30										
27 28 30										
28										
30										
CLASS ACTION COMPLAINT – JURY TRIAL DEMANDED										
		CLASS ACT	TION COMPL	LAINT – JURY	TRIAL DEMAND	DED				

<u>CLRA Venue Declaration Pursuant to California Civil Code Section 1780(d)</u>
I, Neal J. Deckant, declare as follows:

I am counsel for Plaintiffs, and I am a partner at Bursor & Fisher, P.A. I make this declaration to the best of my knowledge, information, and belief of the

facts stated herein.

2. The complaint filed in this action is filed in the proper place for trial because many of the acts and transactions giving rise to this action occurred in this District, and because Plaintiff C.B. resides in this District.

3. Plaintiff C.B. alleges that he is a citizen of California and resident of Encinitas, California.

4. Defendant Ashlynn Marketing Group is a California corporation with its principal place of business in Santee, California.

I declare under penalty of perjury under the laws of the United States and the State of California that the foregoing is true and correct, executed on April 13, 2023 at Walnut Creek, California.

> /s/ Neal J. Deckant Neal J. Deckant

CLASS ACTION COMPLAINT – JURY TRIAL DEMANDED

JS 44 (Rev. 10/20) Case 3:23-cv-00669-L-BGS CPORT OF TER FOR 13/23 Page 1 of 1 The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.) I. (a) PLAINTIFFS **DEFENDANTS** C.B. and R.V.H., individually and on behalf of all others ASHLYNN MARKETING GROUP, INC., similarly situated, (b) County of Residence of First Listed Plaintiff San Diego County of Residence of First Listed Defendant (EXCEPT IN U.S. PLAINTIFF CASES) (IN U.S. PLAINTIFF CASES ONLY) IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED. NOTE: (c) Attorneys (Firm Name, Address, and Telephone Number) Attorneys (If Known) Neal J. Deckant, Bursor & Fisher, P.A. 1990 N. California Blvd., Suite 940, Walnut Creek, CA 94596 '23CV0669 L BGS Tel.: (925) 300-4455 II. BASIS OF JURISDICTION (Place an "X" in One Box Only) III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff (For Diversity Cases Only) and One Box for Defendant) 1 U.S. Government 3 Federal Ouestion PTF DEF PTF DEF Citizen of This State **X** 1 Incorporated or Principal Place 4 **X** 4 Plaintiff (U.S. Government Not a Party) 1 of Business In This State 2 U.S. Government **X** 4 Diversity 2 Incorporated and Principal Place 5 Citizen of Another State 2 5 of Business In Another State Defendant (Indicate Citizenship of Parties in Item III) Citizen or Subject of a 3 3 Foreign Nation 6 6 Foreign Country IV. NATURE OF SUIT (Place an "X" in One Box Only) Click here for: Nature of Suit Code Descriptions CONTRACT TORTS FORFEITURE/PENALTY BANKRUPTCY **OTHER STATUTES** 110 Insurance PERSONAL INJURY PERSONAL INJURY 625 Drug Related Seizure 422 Appeal 28 USC 158 375 False Claims Act 365 Personal Injury -120 Marine 310 Airplane of Property 21 USC 881 423 Withdrawal 376 Qui Tam (31 USC 130 Miller Act 315 Airplane Product Product Liability 28 USC 157 3729(a)) 690 Other 140 Negotiable Instrument Liability 367 Health Care/ 400 State Reapportionment PROPERTY RIGHTS 150 Recovery of Overpayment 320 Assault, Libel & Pharmaceutical 410 Antitrust & Enforcement of Judgment Slander Personal Injury 820 Copyrights 430 Banks and Banking 151 Medicare Act 330 Federal Employers' Product Liability 830 Patent 450 Commerce 152 Recovery of Defaulted Liability 368 Asbestos Personal 835 Patent - Abbreviated 460 Deportation 340 Marine 470 Racketeer Influenced and Student Loans Injury Product New Drug Application (Excludes Veterans) 345 Marine Product Liability 840 Trademark Corrupt Organizations 153 Recovery of Overpayment Liability PERSONAL PROPERTY LABOR 880 Defend Trade Secrets 480 Consumer Credit X 370 Other Fraud (15 USC 1681 or 1692) 350 Motor Vehicle of Veteran's Benefits 710 Fair Labor Standards Act of 2016 355 Motor Vehicle 160 Stockholders' Suits 371 Truth in Lending Act 485 Telephone Consumer 190 Other Contract Product Liability 380 Other Personal 720 Labor/Management SOCIAL SECURITY Protection Act 195 Contract Product Liability 490 Cable/Sat TV 360 Other Personal Property Damage Relations 861 HIA (1395ff) 196 Franchise Injury 385 Property Damage 740 Railway Labor Act 862 Black Lung (923) 850 Securities/Commodities/ 362 Personal Injury -863 DIWC/DIWW (405(g)) Product Liability 751 Family and Medical Exchange Medical Malpractice Leave Act 864 SSID Title XVI 890 Other Statutory Actions PRISONER PETITIONS **REAL PROPERTY** CIVIL RIGHTS 790 Other Labor Litigation 865 RSI (405(g)) 891 Agricultural Acts 210 Land Condemnation 440 Other Civil Rights 791 Employee Retirement 893 Environmental Matters Habeas Corpus: 895 Freedom of Information 220 Foreclosure 441 Voting 463 Alien Detainee Income Security Act FEDERAL TAX SUITS 230 Rent Lease & Ejectment 442 Employment 510 Motions to Vacate 870 Taxes (U.S. Plaintiff Act 240 Torts to Land 443 Housing/ Sentence or Defendant) 896 Arbitration 245 Tort Product Liability Accommodations 530 General 871 IRS-Third Party 899 Administrative Procedure 26 USC 7609 290 All Other Real Property 445 Amer. w/Disabilities 535 Death Penalty IMMIGRATION Act/Review or Appeal of Employment Other: 462 Naturalization Application Agency Decision 465 Other Immigration 446 Amer. w/Disabilities 540 Mandamus & Other 950 Constitutionality of 550 Civil Rights Other Actions State Statutes 448 Education 555 Prison Condition 560 Civil Detainee -Conditions of Confinement V. ORIGIN (Place an "X" in One Box Only) 2 Removed from 4 Reinstated or 6 Multidistrict 8 Multidistrict Original 3 Remanded from 5 Transferred from Proceeding State Court Appellate Court Reopened Another District Litigation -Litigation -Direct File (specify) Transfer Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity): 28 U.S.C. § 1332(d) VI. CAUSE OF ACTION Brief description of cause: Defendant failed to disclose material facts VII. REOUESTED IN CHECK IF THIS IS A CLASS ACTION **DEMAND \$** CHECK YES only if demanded in complaint: X

COMPLAINT	I : UNDER RULE	23, F.R.Cv.P.	\$5,000,000+	JURY DEMAND:	X Yes	No
VIII. RELATED (IF ANY	CASE(S) (See instructions):	JUDGE		DOCKET NUMBER		
DATE		SIGNATURE OF ATT	FORNEY OF RECORD			
Apr 13, 2023		/s/ Neal J. Deckant				
FOR OFFICE USE ONLY						
RECEIPT #	AMOUNT	APPLYING IFP	JUDGE	MAG. JUDGI	Е	